Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Aimmune, Allen, behavior, blended, borrowing, CCPA, Celia, cellular, chemotherapy, Circuit, codified, collateralized, compromise, context, crime, CRR, database, downsizing, dubbed, Eckert, embedded, epithelial, EU, evolve, evolving, excluded, Fisher, fusion, GDPR, Gilead, hemolytic, inactivity, incremental, inline, input, insolvency, intrusion, Jazz, killing, leadership, lessee, lifted, mark, mobile, monotherapy, movement, NaN, network, obexelimab, ORR, overseeing, overspending, Patheon, pharmacokinetic, pharmacologic, plamotamab, prevalent, progressing, proliferation, rare, reject, remanded, reschedule, residual, retired, RSU, secretary, sophistication, Sr, SSP, tafasitamab, tenant, theft, Thermo, tracing, transmembrane, Umbrella, uremic, vir, VirBio, whichever, word, Yang
Removed:
ACR, admitting, AE, al, allergic, apparent, approving, area, argument, arm, array, assuming, asthma, AstraZeneca, atopic, attack, background, baseline, belimumab, Benlysta, beta, Biogen, breached, captioned, certified, Chancery, classification, College, complaint, confounding, Consulting, core, count, creation, DePinto, detectable, diarrhea, die, discomfort, diversity, Dohme, Duty, earliest, emerging, exceeded, fever, fewer, fiduciary, finalized, GlaxoSmithKline, half, headache, hypersensitivity, IgE, immunogenicity, improvement, infusion, initiating, integral, invested, IV, lawsuit, lenalidomide, Lloyd, lowest, lt, manageable, mechanism, median, mediation, Merck, modulating, nausea, neutralize, Nordisk, Novo, Nucala, numerically, observe, occurrence, optimization, oral, placebo, platelet, plc, predominant, principle, proportion, pyrexia, quickly, randomized, reaction, recapitalization, reception, reducing, Regeneron, remission, representing, rescue, responder, Rheumatology, RI, Rituxan, rituximab, robust, Rowland, scaffold, secondary, serum, Sharp, showed, small, source, statistically, threatening, thrombocytopenia, timeframe, transient, travel, underwriting, urticaria, verified, vomiting, warrant, wrongdoing, Xolair
Filing tables
Filing exhibits
Related press release
Associated XNCR transcripts
XNCR similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Nos. 333-192635 and 333-216365) on Form S-8 and the Registration Statement (No. 333-213700) on Form S-3 of Xencor, Inc. of our reports dated February 24, 2020, relating to our audits of the financial statements and the effectiveness of internal controls over financial reporting of Xencor, Inc., appearing in this Annual Report on Form 10-K of Xencor, Inc. for the year ended December 31, 2019.
/s/ RSM US LLP
Los Angeles, California
February 24, 2020